Pharmacy-based expansion of buprenorphine access.
J Subst Use Addict Treat
; 157: 209195, 2024 02.
Article
em En
| MEDLINE
| ID: mdl-37858795
ABSTRACT
INTRODUCTION:
Access to evidence-based medication treatment is a challenge for most Americans with opioid use disorder. New models of collaborative care that actively incorporate pharmacists are being trialed.METHODS:
We author a commentary based on our experiences providing clinical care as part of a randomized controlled trial of pharmacy-based addiction care.RESULTS:
This commentary describes some of the experiences of working with a Collaborative Practice Agreement between pharmacists and physicians to provide pharmacy-based, low-threshold buprenorphine access.CONCLUSION:
Given that 87â¯% of Americans with opioid use disorder are not getting access to buprenorphine or methadone, establishing a pharmacy-based buprenorphine treatment program is a promising strategy to address that gap and should be explored promptly.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Farmácia
/
Buprenorfina
/
Transtornos Relacionados ao Uso de Opioides
Limite:
Humans
Idioma:
En
Revista:
J Subst Use Addict Treat
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos